Corcept Therapeutics Incorporated
CORT
株式のランク
#1695
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
株価
$116.87
最終同期: 2026-10-20
時価総額
$12.63B
変化（1日）
4.25%
変化（1年）
55.01%
国
US
取引 Corcept Therapeutics Incorporated (CORT)
カテゴリー
Healthcare
Corcept Therapeutics Incorporated（CORT）の収益
Jun 2026 時点の収益 TTM: $830.81M
Corcept Therapeutics Incorporated の最新の財務報告によると、現在の収益 (TTM) は $830.81M です。2023 年には $482.38M の収益があり、これは 2022 年の $401.86M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Corcept Therapeutics Incorporated の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $830.81M | 23.08% |
| 2024 | $675.04M | 39.94% |
| 2023 | $482.38M | 20.04% |
| 2022 | $401.86M | 9.80% |
| 2021 | $365.98M | 3.42% |
| 2020 | $353.87M | 15.46% |
| 2019 | $306.49M | 21.99% |
| 2018 | $251.25M | 57.82% |
| 2017 | $159.20M | 95.77% |
| 2016 | $81.32M | 61.72% |
| 2015 | $50.29M | 89.39% |
| 2014 | $26.55M | 156.36% |
| 2013 | $10.36M | 213.18% |
| 2012 | $3.31M | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | $29.00K | -86.12% |
| 2008 | $209.00K | -56.64% |
| 2007 | $482.00K | 63.95% |
| 2006 | $294.00K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $2.54B | 205.24% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $4.88B | 487.88% |
HK
|
